source
- Setara Biosciences raises $90 million Series A to advance Jazz-spun rare disease programsSetara Biosciences has been created to focus on a set of rare-disease assets that Jazz Pharmaceuticals retained after acquiring Actio Biosciences. The new company secured $90 million in Series A f…
- FDA rolls out new inspection coordination plan, lifts estradiol patch warning and HHS permits compounding of six peptidesFDA's drug center and inspections office have agreed on a new concept of operations (ConOps) to better coordinate inspections and compliance activities. A U.S. senator introduced draft legislation…